Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BIOKAD, AO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Study of PK, PD, Safety of Multiple Intravenous Injections of BCD-066 and Aranesp in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2018-10-03

Last Posted Date: 2020-04-21

Lead Sponsor: Biocad

Target Recruit Count: 57

Registration Number: NCT03693950

Locations: 🇷🇺
BIOCAD, Saint Petersburg, Strelna, Russian Federation

Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis

Phase 3

Conditions: Psoriatic Arthritis

Interventions: Drug: BCD-085
Drug: Placebo

First Posted Date: 2018-07-26

Last Posted Date: 2021-09-08

Lead Sponsor: Biocad

Target Recruit Count: 194

Registration Number: NCT03598751

Locations: 🇧🇾
1st City Clinical Hospital, Minsk, Belarus
🇷🇺
Chelyabinsk Regional Clinical hospital, Chelyabinsk, Russian Federation
🇷🇺
North-Western State Medical University n.a. I.I.Mechnikov, Saint-Petersburg, Russian Federation

Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2018-06-11

Last Posted Date: 2021-09-08

Lead Sponsor: Biocad

Target Recruit Count: 24

Registration Number: NCT03551275

Locations: 🇷🇺
City Hospital #15, Moscow, Russian Federation
🇷🇺
Moscow Regional Research and Clinical Institute, Moscow, Russian Federation
🇷🇺
Scientific Center of Neurology, Moscow, Russian Federation

and more 2 locations

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

Phase 2

Completed

Conditions: Anemia

First Posted Date: 2018-05-08

Last Posted Date: 2021-03-04

Lead Sponsor: Biocad

Target Recruit Count: 75

Registration Number: NCT03519243

Locations: 🇧🇾
City Clinical Hospital №9, Minsk, Belarus
🇷🇺
City Mariin Hospital, St. Petersburg, Russian Federation
🇷🇺
B.Braun Avitum Russland Clinics Ltd., St.Petersburg, Russian Federation

Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Phase 2

Terminated

Conditions: Liver Cirrhosis, Biliary

First Posted Date: 2018-03-26

Last Posted Date: 2019-10-11

Lead Sponsor: Biocad

Target Recruit Count: 9

Registration Number: NCT03476993

Locations: 🇷🇺
State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation
🇷🇺
North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russian Federation
🇷🇺
Smolensk state medical university, Smolensk, Russian Federation

Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma

First Posted Date: 2018-03-21

Last Posted Date: 2019-05-09

Lead Sponsor: Biocad

Target Recruit Count: 15

Registration Number: NCT03472027

Locations: 🇷🇺
N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation
🇷🇺
JSC "Modern Medical Technologies", Saint Petersburg, Russian Federation
🇷🇺
N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russian Federation

and more 1 locations

A Study of BCD-135 in Patients With Advanced Solid Tumors

Phase 1

Conditions: NSCLC
Renal Cell Carcinoma
Bladder Cancer
Melanoma

Interventions: Drug: BCD-135

First Posted Date: 2018-03-13

Last Posted Date: 2018-03-13

Lead Sponsor: Biocad

Target Recruit Count: 30

Registration Number: NCT03464032

Locations: 🇷🇺
LLC BioEk, Saint-Petersburg, Russian Federation

The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Seropositive RA

Interventions: Biological: BCD-089, 162 mg, s/c, qw
Drug: placebo
Biological: BCD-089, 162 mg, s/c, q2w

First Posted Date: 2018-03-07

Last Posted Date: 2021-11-18

Lead Sponsor: Biocad

Target Recruit Count: 105

Registration Number: NCT03455842

Locations: 🇧🇾
1st City Clinical Hospital, Minsk, Belarus
🇷🇺
Chelyabinsk Regional Clinical hospital, Chelyabinsk, Russian Federation
🇷🇺
Kazan State Medical University, Kazan, Russian Federation

and more 1 locations

International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis

Phase 3

Active, not recruiting

Conditions: Ankylosing Spondylitis

Interventions: Drug: BCD-085
Other: placebo

First Posted Date: 2018-02-27

Last Posted Date: 2023-02-21

Lead Sponsor: Biocad

Target Recruit Count: 228

Registration Number: NCT03447704

Locations: 🇷🇺
Non-governmental Healthcare Institution "Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways", Chelyabinsk, Russian Federation
🇷🇺
Chelyabinsk Regional Clinical hospital, Chelyabinsk, Russian Federation
🇷🇺
Kazan State Medical University, Kazan, Russian Federation

and more 4 locations

An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis

Phase 3

Completed

Conditions: Moderate to Severe Plaque Psoriasis

Interventions: Drug: BCD-085 Q2W
Drug: BCD-085 Q4W
Drug: Placebo

First Posted Date: 2018-01-04

Last Posted Date: 2022-06-01

Lead Sponsor: Biocad

Target Recruit Count: 213

Registration Number: NCT03390101

Locations: 🇷🇺
BIOCAD, Saint Petersburg, Strelna, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy